DREADD agonist 21

• Description :

  DREADD agonist 21 is a potent human muscarinic acetylcholine M3 receptors (hM3Dq) agonist (EC50=1.7 nM) [1].

• UNSPSC :

  12352005

• Hazard Statement :

  H302, H315, H319, H335

• Target :

  MAChR

• Type :

  Reference compound

• Related Pathways :

  GPCR/G Protein; Neuronal Signaling

• Applications :

  Neuroscience-Neuromodulation

• Field of Research :

  Neurological Disease

• Assay Protocol :

  https://www.medchemexpress.com/DREADD-agonist-21.html

• Purity :

  99.46

• Solubility :

  DMSO : ≥ 78 mg/mL

• Smiles :

  C12=CC=CC=C1NC3=CC=CC=C3C(N4CCNCC4)=N2

• Molecular Formula :

  C17H18N4

• Molecular Weight :

  278.35

• Precautions :

  H302, H315, H319, H335

• References & Citations :

  [1]Chen X, et al. The first structure-activity relationship studies for designer receptors exclusively activated by designer drugs. ACS Chem Neurosci. 2015 Mar 18;6 (3) :476-84.|[2]Thompson KJ, et al. DREADD Agonist 21 Is an Effective Agonist for Muscarinic-Based DREADDs in Vitro and in Vivo. ACS Pharmacol Transl Sci. 2018 Sep 14;1 (1) :61-72.

• Shipping Conditions :

  Room Temperature

• Storage Conditions :

  -20°C, 3 years; 4°C, 2 years (Powder)

• Scientific Category :

  Reference compound1

• Clinical Information :

  No Development Reported

• Isoform :

  MAChR3

• Citation 01 :

  Brain Res Bull. 2021 Aug:173:66-73.|bioRxiv. 2025 Oct 9.

• CAS Number :

  [56296-18-5]